Autologous Epstein–Barr virus‐specific adoptive T‐cell therapy in a patient with lupus nephritis
Dwarakanathan Ranganathan(Griffith University), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Corey Smith(QIMR Berghofer Medical Research Institute), Sharad Ratanjee(The University of Queensland), Monica Suet Ying Ng(Queensland Health), Archana Panikkar(QIMR Berghofer Medical Research Institute), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Shannon E. Best(QIMR Berghofer Medical Research Institute), George John(Department of Biotechnology), Hilary Reddiex(QIMR Berghofer Medical Research Institute), Saskia Leibowitz(Royal Brisbane and Women's Hospital), Leone Beagley, Jyothy Raju(QIMR Berghofer Medical Research Institute), George Ambalathingal(The University of Queensland)
Cited by 3
Related Papers
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
|The Journal of Experimental Medicine|1992|391
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
|Proceedings of the National Academy of Sciences|1999|332
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.
|The Journal of Experimental Medicine|1994|276
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261